Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai Inc. has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “n ...

Biogen and Eisai have announced that the US Food and Drug Administration (FDA) has accepted a Biologics License Application ...

An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...

U.S. biotech company Biogen, which commercialized a new treatment for Alzheimer's disease in collaboration with Japanese pharmaceutical company Eisai,... Celltrion targets innovative drug ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...